South Korea to Introduce Sunshine Laws to Tackle Corruption in Pharmaceutical Industry

SEOUL, June 27 – The South Korean government is introducing new legislation in its fight against corruption, including regulations that will require pharmaceutical companies to divulge payments made to doctors and pharmacists starting next year. Under the new health care reform, pharmaceutical companies that offer financial compensation to medical staff are required to keep records of all the transactions, which must be presented at the request of the minister of Health and Welfare (MOHW), the ministry announced on Monday. Often called in the industry as the ‘K-Sunshine Act’ given its similar nature to the Physician Payments Sunshine Act in the U.S., …

Read More »

Ontario doctors go to court to keep billing information secret

Two groups of doctors and the Ontario Medical Association are headed to court Monday to argue that OHIP payments to top-billing physicians are “personal information” and should not be public. The information and privacy commissioner last year ordered the public disclosure of the top billers’ identities, along with amounts each receives in payments from the taxpayer-funded insurance plan. The information is business-related, not personal, and should be public because of the importance of transparency of government expenditures, the ruling said. A judicial review of that decision is being sought by the OMA and two groups of doctors — known in …

Read More »

Canada : Open Pharma wants public to know ties between MDs and pharmaceutical industry

Canada is seen as an international “laggard” when it comes to transparency about financial ties between the pharmaceutical industry and physicians. If you live in the United States, you can easily find out if your doctor receives payments from drug companies. Ditto if you live in Australia, Japan, the United Kingdom, France, Denmark and many other European countries. But not Canada. This country is seen as an international “laggard” when it comes to transparency about financial ties between the pharmaceutical industry and physicians. But there is a growing chorus of voices demanding change in the name of quelling concerns about …

Read More »

Australia | Pharma reporting still leaves gaps in money trail

The latest figures on drug company spending on healthcare professionals have been released, with six out of 35 companies putting more than the $1 million each into funding event registrations, travel and accommodation costs, fees for service and consultancies. Pfizer topped the list at nearly $1.9 million in total spending, followed by Boehringer Ingelheim at $1.38 million, while Bayer spent just over $1.2 million. The other companies with payments of more than $1 million were AstraZeneca, Novartis and BMS. Analysis showed an average spending of $600,000 per company between 1 May and 31 October 2016, with the lowest spending by …

Read More »

South Korea: Implementation Details Of Korea’s « Sunshine Act » Under Discussion.

On June 3, 2017, Korea’s version of the « Sunshine Act » will go into effect. Article 47-2 of the Pharmaceutical Affairs Act and Article 13-2 of the Medical Devices Act of Korea require all pharmaceutical and medical device companies to establish and maintain an expense reporting system to collect and report on economic benefits provided to healthcare professionals (« Expense Reporting System »). Under this newly required Expense Reporting System, pharmaceutical and medical device companies are now required to collect and keep records of any economic benefit provided to a medical institution or healthcare professional and prepare an expense report on such economic …

Read More »

Anti-corruption: All roads lead to enforcement

When it comes to corruption, Life Sciences companies are a frequent target of investigation and enforcement. The French enactment of Sapin II is the latest in a long line of laws to combat corruption. This article explores Sapin II and why the authors feel that Life Sciences companies are among the best positioned to comply with Sapin II’s requirements. To read the article by Amy Greenstein, Caroline Franco, Darren Jones and Veronique Monjardet

Read More »